Exelixis Inc (EXEL)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 1,077
- Market Cap
- $14.1B
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
SentiSense also tracks daily options readings for Exelixis Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Exelixis Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.